For many years, medical professionals have explored the use of electrical stimulation to combat depression. Now, a Houston-based startup, Motif Neurotech, is taking this concept to new heights by developing a smaller, less invasive solution that could potentially be used at home.
Motif Neurotech has secured FDA approval for an Investigational Device Exemption, paving the way for an early feasibility study of a groundbreaking brain-stimulation device aimed at individuals suffering from treatment-resistant depression. This device, known as the Motif DOT XCS System, features a compact implant that is placed within the skull, just above the brain's protective layer, delivering electrical pulses to a brain network associated with depression.
While the upcoming study will not confirm the device's efficacy, it will assess the safety of the implant and the procedure over a 12-month period. If successful, this innovation could serve as a viable alternative between non-invasive treatments like transcranial magnetic stimulation (TMS) and more invasive procedures such as deep brain stimulation.
A New Approach to Brain-Computer Interfaces
Brain-computer interfaces (BCIs) are typically associated with aiding individuals with paralysis in communication and control. However, Motif is redirecting this technology towards psychiatric care, aiming to adjust brain activity linked to depression through stimulation.
The FDA's approval allows Motif to initiate the RESONATE study, which will focus on individuals whose depression has persisted despite trying at least two different antidepressant medications. The research will prioritize safety while also observing changes in depression symptoms, anxiety, cognitive function, and overall quality of life.
The trial will involve a limited group of participants, potentially across eight medical institutions, including Baylor College of Medicine and Massachusetts General Brigham. Dr. Sameer Sheth, a neurosurgeon at Baylor and principal investigator of RESONATE, highlighted the urgent need for new options for those with treatment-resistant depression, a condition that significantly contributes to disability and suicide rates globally.
Minimally Invasive Procedure
Motif's design aims to transform what is often perceived as an intimidating surgical procedure into a simple outpatient visit. The device is implanted in the skull, above the dura mater, avoiding direct contact with brain tissue.
"We replace a small piece of bone with an electronic device, secure it with a protective cap, and stitch the skin back up," explained Jacob Robinson, co-founder and CEO of Motif. "The entire process takes about 15 minutes and doesn't involve penetrating brain tissue."
This innovative placement strategy is crucial for Motif's vision. By minimizing the surgical complexity, the company hopes to make this treatment more accessible compared to traditional deep brain stimulation, which typically requires a more intricate procedure.
The implant is designed to be small, with the power source located externally. During treatment, patients would wear a cap that wirelessly transmits energy to the device, allowing for brief stimulation sessions tailored to their needs.
Motif's approach targets the central executive network of the brain, which plays a vital role in focus and planning. By stimulating this network, the company aims to enhance neuroplasticity, potentially helping patients regain control over their daily lives.
As the RESONATE trial unfolds, it represents a significant step towards understanding whether this innovative device can offer hope to those who have exhausted traditional treatment options, marking a potential breakthrough in the fight against depression.